The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwCLL 2019 | Predictors in the novel therapy era
Richard Rosenquist, MD, PhD, from Karolinska University Hospital, Solna, Sweden, and John Seymour, MBBS, PhD, Peter MacCallum Cancer Center, Victoria, Australia, speaking at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK. Dr Rosenquist and Dr Seymour discuss biological predictors, such as p53 mutations, and their implications on chronic lymphocytic leukemia (CLL) treatment.
